The fda will not allow genr to enter a phase 3 based on the trial in Mexico. It was a proof of concept trial and the results were as hoped.
I think genr is at the point where they can do their 125 to 150 million up front deal with a big pharma.
One thing that no one has brought up has been a different delivery system for squalamine. I believe in the next phase 2 you will not see 4 weekly infusions but an intranasal or intradermal delivery making it more user friendly.
It will also make the maintenance therapy more conveniant. Anyway after the deal is done it will be in big pharma's hands and they will know how to run with it.
genr will then be able to concentrate on hclca1(mucoregulator) and msi-1436(obesity and diabetes)
News 
Market Data 
Discover 
